Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Placebo-controlled, Double-blind, Multiple Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis
Conditions
Interventions
TCK-276
TCK-276 Placebo
Locations
8
United States
Orange County Research Center
Tustin, California, United States
St. Jude Clinical Research, LLC
Doral, Florida, United States
SouthCoast Research Center, Inc
Miami, Florida, United States
Allied Biomedical Research Institute
Miami, Florida, United States
San Marcus Research Clinic, Inc.
Miami Lakes, Florida, United States
Floridian Clinical Research, LLC
Miami Lakes, Florida, United States
Start Date
August 10, 2022
Primary Completion Date
July 20, 2023
Completion Date
July 27, 2023
Last Updated
October 15, 2024
NCT06329401
NCT07048197
NCT06647069
NCT07484243
NCT06841562
NCT07268326
Lead Sponsor
Teijin America, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions